急性淋巴細(xì)胞白血?。ˋcute lymphoblastic leukemia，ALL）是一種血液性的惡性腫瘤，在成人急性白血病中較為常見。白血病細(xì)胞的生物學(xué)特征是涉及前體淋巴細(xì)胞增殖分化相關(guān)的染色體異常和基因改變。盡管聯(lián)合化療方法已取得重大進(jìn)展，但耐藥性及復(fù)發(fā)性仍為治療的難題，因此就ALL基因方面的機(jī)制通路，及靶向治療藥物進(jìn)行綜述，旨在為臨床新藥研發(fā)提供參考。

Acute lymphoblastic leukemia is a hematological malignant tumor, which is more common in adult acute leukemia. The biological characteristics of leukemic cells are chromosomal abnormalities and genetic alterations related to the proliferation and differentiation of precursor lymphocytes. Although significant progress has been made in combination chemotherapy, medicine resistance and relapse are still difficult problems in treatment. Therefore, the mechanism of ALL gene mutation, pathway and targeted therapy are reviewed in this paper, in order to provide reference for clinical new drug research and development.